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When the first cases of HIV infection first surfaced in the 1980s, AIDS was a deadly 
disease without any therapeutic alternatives. Currently, there is still no cure for the most 
cases mainly due to the multiple tissues that act as a reservoir for this virus besides the 
high viral mutagenesis leading to antiretroviral drug resistance. Throughout the years, 
multiple drugs with specific mechanisms of action on distinct targets have been 
approved. Nowadays, a standard antiretroviral therapy must be composed of several 
antiretrovirals targeting multiple phases of the virus’ replication cycle. Although the 
combination antiretroviral therapy (c-ART) is effective in reducing viral load to 
undetectable levels, it also presents few disadvantages regarding side effects, frequency 
of administration and the possibility of drug resistance. In this context, several new 
drugs (including novel targets) and vaccines are being now tested in pre-clinical and 
clinical trials for HIV management. Regarding the drug delivery, an attempt to change 
the route of administration of some conventional antiretrovirals has proven to be 
successful and surpassed some issues related with patient compliance. Accordingly, 
nanotechnology has brought a new approach to overcoming these inconveniences as 
well as certain formulation obstacles (e.g. drug solubility and biodistribution). The 
encapsulation of antiretroviral drugs into nanosystems has shown improved drug release 
and pharmacokinetic profiles. In this review, the most recent phase III clinical studies 
and other research therapies as advanced transdermal antiretroviral nanodelivery 






Keywords: HIV; Clinical Trials; New Antiretrovirals; Vaccines; Advanced Transdermal 
Nanodelivery Systems; Antiretroviral Therapy 
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Resumo 
 
Aquando do aparecimento dos primeiros casos de infeção por HIV na década de 1980, 
tratava-se de uma doença letal para a qual não existiam alternativas terapêuticas. 
Atualmente, ainda não existe uma cura, sobretudo devido aos tecidos que servem como 
reservatórios do vírus. Ao longo dos anos, muitos fármacos foram aprovados, com 
diferentes alvos para diversificar a estratégia terapêutica. Atualmente, um regime 
terapêutico convencional deverá ser composto por vários fármacos, que atuem sobre 
diversas fases do ciclo de replicação do vírus. A terapêutica antirretrovírica combinada, 
apesar de eficaz em reduzir a carga viral para níveis indetetáveis, tem algumas 
desvantagens, nomeadamente, efeitos adversos, a frequência de administração e a 
possibilidade de resistência aos fármacos, devido à elevada taxa de mutação do HIV. 
Neste sentido, vários novos fármacos e vacinas estão a ser testados em ensaios clínicos 
e pré-clínicos para o controlo da infeção. Além de novos fármacos pertencentes às 
classes terapêuticas já conhecidas, existem novas classes de fármacos a ser estudadas 
em ensaios clínicos, com novos alvos e novos mecanismos de ação. Além disto, existem 
novas vacinas a ser testadas como uma possível solução para erradicar reservatórios 
virais e possivelmente eliminar a infeção por completo. No que toca à veiculação de 
fármacos, está a ser feita uma tentativa de modificar a via de administração de alguns 
antirretrovirais convencionais no sentido de ultrapassar alguns problemas dos doentes 
em relação a adesão à terapêutica. Por fim, a nanotecnologia trouxe uma nova 
abordagem para ultrapassar obstáculos de formulação, nomeadamente a solubilidade do 
fármaco. A encapsulação de antirretrovirais em nanosistemas tem-se revelado 
promissora no que toca a melhorar a libertação dos fármacos e o seu perfil 
farmacocinético. Nesta monografia serão abordados os ensaios clínicos mais recentes, 
bem como algumas terapias ainda sob investigação, como nano sistemas de veiculação 
transdérmica.    
 
 
Palavras-chave: HIV; Ensaios Clínicos; Antirretrovirais; Vacinas; Nanosistemas de 
Veiculação Transdérmica; Terapêutica Antiretrovírica  
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Methods 
 
The research for this literature overview was based on electronic sources, mostly from 
the PubMed database, the EMA database, and the ClinicalTrials.gov database.  Most of 
the research was performed between early March and October 2019, and sporadically, 
outside this period. Based on the analysis of literature, the most relevant articles were 
selected. Regarding article selection, there were no restrictions with language; 
nevertheless, all sources cited in this review were written in English. The publication 
dates of these sources ranged from 2001 to 2019. During research and selection of the 
information, there was always a concern with obtaining the most reliable information 
published in journals, reports and web pages. At the end, 97 references were included in 
this review.    
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1. Introduction 
The human immunodeficiency virus (HIV) is still a very prominent issue in worldwide 
health. AIDS can now be considered a chronic infection since patients are living longer 
due to several options of antiretroviral therapy (1).  The number of new cases 
(incidence) has decreased from 3.3 million in 2002 to 1.6 million in 2012, nevertheless, 
as of 2018, an estimated 37.9 million people are living with HIV and 1.7 million are 
newly infected (1,2). 
The transmission of this virus was originated from several different zoonotic infections 
combined with simian immunodeficiency viruses (SIV) in African primates, such as 
chimpanzees from Central Africa and sooty mongabey monkeys from West Africa in 
the case of HIV-1 and HIV-2, respectively. Reports indicate that the infection of the 
human population with this virus occurred between 1920 and 1940 probably with 
bushmeat hunters (1,3) 
Phylogenetically, HIV is part of the genus Lentivirus, the family Retroviridae and the 
sub-family Orthoretrovirinae. In terms of genetic and viral characteristics, it can be 
divided into two types, HIV-1 and HIV-2 (3). 
There are four different groups of HIV-1: M; N; O and P. Group M can be further 
subdivided into subtypes A to D, F to H, J and K (3). Subtype C is more prevalent in 
Africa and India, whereas subtype B predominates in Americas, Australia and Western 
Europe. HIV-2, in turn, is mostly circumscribed to West Africa (1). The genetic 
diversity of HIV-1 can be explained by the fault-prone functioning of the reverse 
transcriptase, which leads to a very high mutation rate and an increased incidence of 
circulating recombinant subtypes. This diversity represents a hard obstacle to the 
efficacy of the current therapies (1). 
1.1. Genomic Structure of HIV  
The HIV genome is formed by two identical single chain RNA molecules, confined to 
the core of the virus particle. This virus particle produces an enzyme, known as reverse 
transcriptase, responsible for the transcription of the viral RNA into the pro-viral 
(double-chained) DNA, which can be integrated into the human genome, due to the 
function of another viral protein, the integrase (IN). The original viral RNA is then 
degenerated (3).  
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The viral genome is delimited at both ends by long term repeat sequences (LTR) 
(Fig.1). One end at the 5’ region codes for the promotor of viral genes transcription. It is 
followed by the group-specific antigen (gag) gene (direction 5’ to 3’), which codes for 
the outer core matrix protein (MA/p17), the capsid protein (CA/p24), the nucleocapsid 
and a nucleic-acid stabilizing protein. The gag gene is followed by the polymerase (pol) 
gene, which is responsible for the production of the reverse transcriptase (RT), the 
RNase H, and viral integrase which degrades the viral RNA and incorporates the viral 
DNA into the human genome, respectively. Next envelope (env) gene codes for two 
membrane proteins gp140 (transmembrane protein, TM) and gp120 (surface 
glycoprotein SU) (3). 
 
Fig.1: Genomic structure of the HIV virus.  LTR: long-term repeat sequences, which are not translated into proteins. 
The one end at the 5’ region works as a promotor of the transcription of all the other genes. gag: group-specific 
antigen; pol: polymerase; env: envelope. In HIV-2, the vpx takes the place of the vpu gene. The HIV-1 genome is 
composed of 9.600 nucleotides whereas the HIV-2 genome has roughly 9.800 nucleotides.  R.C.2019. 
 
Besides these main proteins, there are others with important functions regarding the 
initiation of the viral replication, such as tat, the transactivator protein which activates 
the transcription of viral genes, and rev that regulates the splicing process of the viral 
RNA (3). On the other hand, Vpu, Vpr and Vif play an important role on viral replication 
and infectiousness. The fact that HIV-2 encodes for Vpx instead of Vpu, explains its 
diminished pathogenicity compared to HIV-1 (3). 
1.2. Viral Particle Structure 
The viral HIV particle is round and measures about 100 nm in diameter. Its outer lipid 
membrane, the envelope, is formed by a lipid bilayer and trimers of the envelope 
proteins, more specifically, trimers of gp120, are connected to the membrane through 
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trimers of gp41 (Fig.3). The envelope covers the external capsid membrane, which in 
turn is composed by the matrix protein (MA). Inside this membrane, there is a cone 
shaped capsid formed by the capsid protein p24. Within the capsid lays the genetic 
material of the virus composed by two single-stranded RNA molecules, surrounded by 
viral enzymes, such as RT, RNase H and IN, which are directly linked to the nucleic 
acid. Finally, some oligopeptides can be also found within the capsid upon the release 
of virions from the infected cell, through a phenomenon called proteolytic processing 
(3). 
 Fig.2:  HIV-1 Viral particle structure. The HIV virion is composed of many structural proteins such as gp120 and 
gp41 in the envelope, which protects the outer lipoprotein membrane, composed of matrix protein (MA or p17). 
Inside outer core membrane is the nucleocapsid, to which the capsid protein (CA) is anchored. Inside the 
nucleocapsid is the viral RNA, reverse transcriptase (RT), integrase, protease, and a nucleic acid stabilizing protein 
Adapted from (4).  
 
1.3. HIV tropism and co-receptors 
HIV is a virus with high genetic diversity since the viral reverse transcriptase (RT) can 
easily originate errors in replication. When it comes to the viral tropism, HIV strains 
can be classified either as macrophage-tropic (M-tropic) or as T-cell line tropic viruses. 
M-tropic viruses are non-syncytium inducing (NSI), which means that these viruses do 
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not lead to the formation of multinucleated cells known as syncytia, whereas T-tropic 
viruses are syncytium inducing (SI) (5).  
Regarding the type of co-receptors used for the cell binding process, the HIV virions 
can be classified as R5 viruses if they have tropism for the CCR5 co-receptor, or as X4 
viruses, if they interact with the CXCR4 co-receptor. It might be possible that a viral 
particle uses both co-receptors to infect the target cell, and in this case, it would be 
classified as a R5X4 virus. Generally,  in early stages of infection, R5 viruses are more 
abundant, while X4 or R5X4 viral strains predominate in the late stages of infection 
(6,7).  
The most common change in tropism is the alteration from R5 to X4, usually followed 
by CD4+ cell counts dropping, even though the reverse can also occur. It is known that 
X4 viruses can be found in lower quantity at earlier stage of infection, and then, became 
more frequent at later stages, which means that its evolution might happen due to 
immunodepression. T-tropic X4 viruses are linked to lower circulating CD4+Tcells in 
patients who are both experienced and naïve to antiretroviral therapy (ART) (7). M-
tropic viruses typically infect peripheral blood mononuclear cells (PBMC) throughout 
all stages of the disease, despite being associated with a slower progression (7).  
1.4. Virus entry, infection and replication in target cells 
The first step for a virion to successfully infect a target cell is its binding and 
subsequent entry (Fig.2). This process is mediated by the envelope protein (Env), a 
complex macromolecule formed by a trimer of gp120 and gp41 heterodimers, which are 
significantly glycosylated. Its gp120 subunit is composed by five variable regions 
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Fig.3: HIV replication cycle. The virus replicates in a multi-step process that starts with the connection of the virion         
to the CD4 bs, followed by the connection to the co-receptor, fusion of the envelope and cellular membrane, 
liberation of the viral mRNA, reverse transcription, integration, transcription, viral protein synthesis and finally 
cleavage of polypeptides, viral assembly and release from the host cell. According to the different phases of viral 
replication, there are several different antiretroviral drugs. Adapted from: (1). 
 
Initially, Env binds to the host protein CD4 of T helper cells, macrophages, astrocytes 
and dendritic cells by interacting with the CD4 binding site (CD4 bs) through its gp120 
subunit. In turn, this interaction causes conformational changes in the variable regions, 
V1, V2 and V3. The conformational change in V3 and the formation of β sheet induce a 
conformational change that exposes a new site for the gp120 subunit to bind to the co-
receptor (3,6).  
The co-receptor binding causes a change in the gp41 subunit by disclosing a gp41 
fusion protein (one for each gp41 in the trimer), which will connect to the target cell 
membrane due to its extremely hydrophobic nature, thereby enabling the fusion of both 
viral envelope and host cell membrane (6). The fusion occurs due to the connection of 
the amino-terminal helical regions (HR-N) to the host cell membrane, with the carboxy-
terminal helical regions (HR-C), thus forming a six-helix bundle (6HB). The 6HB 
brings both membrane and envelope together, creating a fusion pore, which allows the 
delivery of viral genetic material into the host cell (6). 
Following the fusion of both virion and host cell, the viral capsid is then absorbed by an 
endosome. Inside the phagocyte, H+ ions are released, causing a decrease in pH value, 
and inducing the delivery of the capsid into the cytoplasm. The viral RT, after being 
activated, will convert the viral single stranded RNA into complementary DNA 
(cDNA), forming a pre-integration complex, which does not possess introns, and 
therefore, can be integrated into the host cell genome, while the RNA strand is 
destroyed by RNase H (3).  
The next step is integration. The cDNA is transported through the cytoplasm and into 
the host cell nucleus via the nucleopores, with the intervention of the Vpr protein. The 
process is fundamentally mediated by the integrase protein (IN), which starts by 
removing nucleotides from the 3’ ends of the proviral DNA, and then proceeds to 
catalyze a nucleophilic attack to the phosphodiester bonds of the DNA chains, thus 
forming a covalent bond between viral and host DNA. This is the essential step in viral 
replication that allows the viral proteins to be produced along with the ones necessary 
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for cellular function, as if they were part of the cell’s own DNA. After the integration 
process is finished, persistent infection is fully established for the infected cell and the 
ones resulting from its division (8,9). 
Once integration is completed, several viral proteins can now be produced through 
transcription using the host cell’s RNA polymerase II. Transcription factors bind to the 
LTR regions and, after a chain of chemical reactions, the regulatory proteins such as 
Tat, Rev and Nef are produced. Tat will activate transcription by connecting its trans-
activation response element (TAR) element to the LTR region (8,9). 
The Gag-Pol protein resulting from the translation of mRNA is transported and 
becomes imbedded into the host-cell’s plasma membrane. This budding process is 
mediated through the gag protein’s L-domains (10).  
Meanwhile, all the other structural viral proteins are being produced and ensembled 
together in the plasma membrane, forming a multiprotein structure. This leads to the 
activation of the most important protein in this entire process, the viral protease (PR), 
which will allow the release of all structural proteins, such as MA, CA and NC, as well 
as  their reorganization into mature virions that can now go on to infect other cells (9). 
In order to the budding process be successful, there must be a great decrease in CD4 
molecules at the surface of the host cell preventing the synergy between them and the 
gp120. Nef, Vpu and Env are the proteins responsible for this task (8). 
1.5. HIV transmission and immunological response 
The primary infection with HIV generally occurs following the exposure of the mucosa 
to the virions, usually after sexual contact with an infected partner.  It can also happen 
by vertical transmission, where an infected mother transmits the virus to her child 
during child-birth, or more rarely, by endovenous transmission during a transfusion of 
infected blood or illicit drug use (1,11,12). 
The period between the infection of the first host-cell and the moment when the virus 
becomes detectable in the blood is called the eclipse phase, and usually lasts from 7 to 
21 days. After the infection of the first cell, the virus continues to replicate in the 
mucosa, submucosa and adjacent lymphatic tissue. The replication concentrates in the 
GALT (gut-associated lymphatic tissue) very early (11,12).  
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What follows is an exponential rise of the viral loading, with the CD4+ cell count 
decreasing rapidly. This results in a symptomatic phase characterized by flu-like very 
non-specific clinical signs that usually last between 7 to 10 days. After a few weeks, the 
host’s immune system is able to generate a response (4,8). 
First starts the cellular immune response, with the activation of CD8+ cytotoxic 
lymphocytes. Their T-cell receptor (TCR) will bind to viral proteins, which are in turn 
connected to MHC I, the antigen-presenting molecule, in order to eliminate the infected 
cells (8). Generally, after 3 to 5 weeks, a humoral response starts to produce specific 
neutralizing antibodies that will destroy the virions via phagocytosis. The convergence 
of both types of immune response leads to a decrease in viremia and a new rise in CD4+ 
cell counts. The period in which there is an infection but without antibodies is called the 
“serological window period” (4). 
Even though this is an asymptomatic phase, and the viral loading is somewhat 
controlled, there is still a loss of immune cells since the virus continues to replicate in 
the lymphatic tissue (its reservoir), destroying its structure. Eventually, without 
antiretroviral therapy, the viral loading becomes higher as the CD4+ cell count 
diminishes, leading to the beginning of the AIDS stage. In this stage,  the patients are 
more susceptible to opportunistic infections such as Mycobacterium tuberculosis, 
Cytomegalovirus, Herpes Zooster and Kaposi’s Sarcoma, among many others  (4) 
1.6. Viral latency 
There are several aspects that make it difficult to eradicate the virus completely once a 
person is infected. One of them is related to the absence of proof-reading activity in the 
viral RT, causing for a great number of mutations and genetic diversity in the HIV 
genome. The other one is about the ability of the virus to infect resting memory or naïve 
cells, leading to a latent viral state (4,8). The huge problem with viral latency is that it 
can occur even after patients have undergone antiretroviral therapy reducing viremia to 
an undetectable level (8). 
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2. Therapeutic Targets vs Commercial Antiretrovirals 
Based on the replication cycle of the HIV, several therapeutic targets and antiretroviral 
drugs have been developed over the years.  In general, antiretrovirals can be classified 
into eight major types, according to their mechanism of action (13,14): 
2.1. Nucleotide/Nucleoside Reverse Transcriptase Inhibitors 
2.2. Non- Nucleotide Reverse Transcriptase Inhibitors 
2.3. Integrase Inhibitors 
2.4. Protease Inhibitors  
2.5. Fusion Inhibitors 
2.6. Pharmacokinetic Enhancers 
2.7. CCR5 Antagonist 
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2.1. Nucleotide/nucleoside Reverse Transcriptase Inhibitors (NRTI) 
The first ones to be developed were the Nucleotide/Nucleoside Reverse Transcriptase 
Inhibitors (NRTI). Their structure is very similar to the one of the viral nucleosides, 
except for the absence of a hydroxyl group in the 3’ position of their deoxyribose sugar, 
thereby preventing a phosphodiester bond between the NRTIs and the next 
5’nucleosides. As a result, the nucleoside chain is interrupted and the proviral DNA is 
not formed. These drugs are formulated and delivered as prodrugs, which need to be 
phosphorylated in order to become active (13,16). NRTIs are classified as competitive 
inhibitors of the RT, as they bind to the enzyme’s active site  being integrated into the 
viral DNA chain (18).  
Regarding pharmacokinetics, this class of drugs is known to have a long intracellular 
half-life period, good oral bioavailability, no restrictions of administration and 
improbable interactions with other drugs (15).  
On the other hand, few side effects have been documented regarding the NRTIs. Some 
of them include myelosuppression, pancreatitis and neuropathy. Also, the NRTIs are 
very prone to inducing resistance mechanisms (13,15). 
The first NRTI to be approved was Zidovudine (AZT) in 1987. The last one to be 
approved was Emtricitabine, in 2003(28).In 1996, studies had already proven the 
efficacy of using a combination of antiretroviral drugs as opposed to monotherapy. 
Nowadays, any initial therapy regimen must have at least three different drugs with 
distinct therapeutic targets (14).  
2.2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
When it comes to reverse transcriptase inhibitors, there are also the Non-nucleoside 
Reverse Transcriptase Inhibitors (NNRTIs), which bind directly to the HIV RT in a 
non- competitive inhibition process (14). NNRTIs bind to a specific pocket of the viral 
RT, away from the RT’s active site, thereby inducing a conformational change that 
inhibits the enzyme’s activity (18). NNRTIs do not inhibit the RT of any other 
retroviruses, nor the one of HIV-2 (16). NNRTIs are quite cheap to produce and permit 
single tablet regimens (17). 
As for adverse effects, NNRTs can cause, among others, rashes, nausea, vomiting, 
fatigue, mood swings depression, jaundice, conjunctivitis and respiratory issues (14).  
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Just like the NRTIs, NNRTIs are very prone to inducing resistance. A simple change in 
an aminoacid in the NNRTI binding pocket of the RT can lead to great resistance, with 
very little changes in viral replication (16).  
The first NNRTI to be approved was Nevirapine (NVP), in 1996, the same year when 
combined antiretroviral therapy (c-ART) was first introduced (17). The most recent 
drug to be approved in this class was Doravirine approved in November 2018 for use 
across the European Union (29). 
2.3. Integrase Inhibitors (IIs) 
In the last decade, the viral integrase has been successfully used as a therapeutic target. 
The integration of viral DNA into the host’s genome is composed of two steps: the first 
one occurs when integrase cleaves the nucleotides at the 3’ end of the host DNA strands 
creating “loose ends”. This is called the 3’ processing reaction. The second step of 
integration is the strand transfer reaction, where integrase, allows the transfer of viral 
DNA to the nucleus, where it will be incorporated into the host genome (13).  
The integrase inhibitors designed until now are really strand transfer reaction inhibitors 
(INSTIs). These inhibitors are quite selective drugs since, through a very unique 
biochemical mechanism, they interact with the co-factors (metallic cations) at the 
enzyme’s active site as well as with the complex formed by viral DNA and integrase. 
The pharmacophore binds to the metallic cations whereas a lipophilic group interacts 
with the viral DNA-integrase complex (16).   
Regarding side effects, INSTIs can cause hypersensitivity reactions, rash, jaundice, 
dark-colored urine, nausea, vomiting, fatigue, blisters in the mouth and skin, diarrhea 
and loss of appetite (14).  
Raltegravir (RAL) was the first integrase inhibitor in 2007. The most recent approval in 
this class of antiretroviral drugs was Elvitegravir in 2014 (17). However, in 2016, the 
drug’s marketing authorization for the European Union was withdrawn for commercial 
reasons (30). 
2.4. Protease Inhibitors (PIs) 
As mentioned in the first chapter, the viral protease is a crucial component of the viral 
replication cycle, because it is responsible for the processing (cleavage) of several 
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precursors, such as gag-pool or gag  into mature proteins and thus, the formation of 
mature virions (13,16).  
Protease inhibitors bind to this enzyme in a competitive manner in the same place as its 
natural substrate. The inhibition of this enzyme’s activity leads to immature virions and 
less viral spreading (16,18). 
The main issue with these antiretroviral drugs is that the protease gene, despite being 
quite small, is very prone to mutation, which can very easily lead to resistance. 
Nevertheless, resistance to PIs is largely a result of the build-up of both primary and 
compensatory mutations acquired in order to restore viral capacity (16). These 
mutations can occur in the protease gene or at the protease’s substrate cleavage sites 
(16). 
Regarding adverse reactions, PIs are known to cause arrhythmia, heartburn, fatigue, 
jaundice, dizziness, abdominal pain, mouth sores and urinary tract issues such as kidney 
stones and dark-colored urine (14).  
Saquinavir (SQV) was the first PI to be approved in 1995 by the FDA and 1996 by the 
EMA (29,31). The most recent approval in this drug category was Darunavir, approved 
by the FDA in 2006 and by the EMA in 2007 (28,29). 
2.5. Fusion inhibitors: Enfuvirtide   
Enfuvirtide is the first drug to be approved as a fusion inhibitor. The fusion between 
viral envelope and CD4 cell membrane is, as discussed previously, mediated by the 
Envelope Glycoprotein (Env), which is composed by the gp120 and gp41subunits. On 
one hand, gp120 enables receptor and co-receptor binding, whereas gp41 allows for the 
concrete fusion of both viral envelope and cell membrane (24).  
Gp41 is the enfuvirtide’s main therapeutic target. The intracellular area is formed by a 
cytoplasmic tail (Cyt). Its extracellular region is composed of several subdomains such 
as the fusion peptide (FP), the fusion peptide proximal region (FPPR), the N-terminal 
heptad repeat (NHR), the C-terminal heptad repeat (CHR), the membrane proximal 
external region (MPER) and the transmembrane domain (TMD) (24,25).  
The connection of gp120 to the target cell co-receptors, either CCR5 or CXCR4, brings 
about changes in the gp41 configuration. The FP will now be unprotected and will then 
enter the target cell membrane, originating a prehairpin structure, which will then shift 
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its conformation to become a “hairpin- like structure”(24,25). Afterwards, the three 
CHR domains are rearranged into the three NHR domains’ trimeric “coiled-coil” 
structure in an anti-parallel sense, forming the 6 helix-bundle (6HB) or “core” 
(24,25).Structurally, enfuvirtide is a synthetic peptide partially similar to the CHR 
region. This gp41 component can be sub-divided into an NHR-binding domain which is 
analogous to Fuzeon®, and a pocket-binding domain (PBD), with hydrophobic pockets 
that bind to the NHR exterior (24). 
Fuzeon® acts by stopping the connection between NHR (also referred to as HR-1(26)) 
and CHR (also referred to as HR-2 (26)) thereby preventing the formation of the 6-HB 
and ultimately the membrane fusion with the viral envelope. Nevertheless, Fuzeon® is 
believed to interfere with other regions of gp41, given that other similar peptides still 
seem to decrease the viral load of some Fuzeon® resistant strains (24).  
Enfuvirtide was approved in 2003 as a treatment option for patients infected with HIV-1 
(given that it is not effective in treating HIV-2), who are in an advanced stage of disease 
progression and are resistant to other antiretroviral drug classes (26). It is taken by 
subcutaneous injection and the standard regimen for an individual older than 16 is 90 
mg twice a day (27). 
The TORO clinical trials demonstrated a few benefits in the administration of 
enfuvirtide in cases where patients have shown resistance to therapy with NRTIs; 
NNRTIs and PIs, with significant decreases in viral load and increases in CD4 cell 
counts (27). 
TORO compared viremia and CD4 cell counts in patients taking both enfuvirtide and an 
optimized conventional ART regimen versus the conventional ART regimen on its own. 
After 48 weeks of treatment, 30% of the enfuvirtide patients had their viremia reduced 
to <400 copies/ml versus 12% in the conventional therapy arm. At a 95 week follow-up, 
17.5% of patients taking enfuvirtide had their viral load at under 50 copies/ml (27). 
Despite being a promising therapeutic option, Fuzeon® has few disadvantages. On one 
hand, it has an inconvenient route of administration, which might bring about issues 
with adherence to therapy (24,27). On the other hand, it has quite a low threshold for 
resistance, which can limit its use in a clinical setting. For the most part, resistance to 
this drug occurs due to mutations in the HR-1 region of gp41, even though some cases 
are explained by mutations in HR-2 (15,27).     
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The most common side effects associated with enfuvirtide use are reactions near the 
injection site, nausea, diarrhea, fatigue and eosinophilia (27). 
     2.5.1 T20 derived lipopeptides 
Despite having a different mechanism of action from other ARV drugs, T20 has limited 
clinical use nowadays for several reasons. Firstly, T20 has a very short half-life, which 
leads to an inconvenient posology (90mg twice a day via subcutaneous injection). Also, 
it has a very low antiretroviral activity and is only active against HIV-1. Finally, T20 
has a very low threshold for resistance (25,32).  
In order to surpass these issues, several T20 based lipopeptides have been synthesized 
over the years. A few examples include LP40, LP46, LP52 and LP80. LP46 was 
synthesized based on another lipopeptide, T1249, which was tested as a second-
generation fusion inhibitor. Although it presented higher antiviral activity than T20, its 
phase II clinical trial was interrupted due to reports of serious side effects (33). In order 
to produce LP46, T1249’s tryptophan rich motif at the C-terminal (TRM) was replaced 
with palmitic acid, a C16 fatty acid (25,32). The result was a T20-derived lipopeptide 
with a much lower IC50 against not only T20 resistant strains, but also some HIV-2 
strains and two SIV strains (32). Also, LP46 was found to be more stable than T20 and 
with higher affinity to the target site (32).  
Taking this into account, other T20 derived lipopeptides have surfaced, such as LP52. 
This molecule was designed based on LP46 and LP40 exhibiting a higher threshold for 
drug resistance and capable of inhibiting T20 resistant strains. Additionally, it has a 
longer half-life and higher antiviral activity with IC50 values as low as picomolar (pM) 
(33). 
In a more recent study (34), several new lipopeptides were developed, using fatty acids 
with different lengths. LP80, with an 18 carbon long fatty acid chain, was found to be a 
quite potent fusion inhibitor against T20 resistant strains, according to a single- cycle 
infection assay. It showed cytotoxicity as LP52 and T20 when tested with PBMCs and 
different cell lines, such as TZM-bl cells, HEK293T cells and MT-4 cells. It also 
showed favorable results in pharmacokinetics studies in healthy rhesus macaques (34).  
When administered at 3mg/kg to rhesus macaques chronically infected with simian-
human immunodeficiency virus (SHIV), once a day for two weeks, viral load was 
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reduced to below the detection limit after 4 days of treatment, in 3 out of 5 monkeys in 
the study (34). 
2.6 Pharmacokinetic enhancers: Cobicistat  
Ever since combination antiretroviral therapy (c-ART) was firstly implemented in 1996, 
it is known that PIs and NNRTIs are metabolized by isoenzymes belonging to the 
CYP450 family, and therefore, interfere with the metabolization process of other very 
commonly taken drugs (23). 
 Also in 1996, it was proven that ritonavir could constrain the metabolization process, 
and therefore, allow for higher concentrations of other antiretrovirals and larger 
intervals in their administration. Thus, ritonavir started to be progressively co-
administered with other first generation PIs such as lopinavir or saquinavir, and 
afterwards with second generation PIs, such as atazanavir and darunavir, always at sub- 
therapeutic doses of 100mg (23).  
Over the years, investigators came to the conclusion that ritonavir is capable of 
interfering with several enzyme subfamilies, such as CYP2C19, CYP2C9 CYP2D6 and 
P-glycoprotein,   being responsible for a huge number of interactions with other drugs 
as well as very unpleasant adverse effects regarding the gastrointestinal tract (23). 
A few years ago, in 2012, cobicistat was approved as a pharmacokinetic booster in co-
administration with other antiretrovirals.  Contrarily to ritonavir, it has no specific 
antiretroviral activity. However, it is substantially more selective than ritonavir, 
considering  that it inhibits only the CYP3A isoenzyme subfamily, which makes 
patients less prone to drug interactions (22,23).  
By inhibiting the CYP3A isoenzymes, cobicistat allows an increasing in the plasma 
concentrations of other antiretrovirals, such as PIs and NNRTIs, thereby enabling higher 
intervals in administration with a lesser pill burden and improved adherence to therapy 
(23).  
Some clinical trials showed an increase in serum creatinine levels and a decrease in 
glomerular filtration rate (GFR) in patients taking cobicistat. Nevertheless, in a phase I 
study, these abnormalities were explained by cobicistat use causing a decline in the 
activity of certain transporters, such as SLC22A2, which are essential for the 
elimination of creatinine. This means that cobicistat causes higher serum creatinine 
levels, thereby altering the GFR estimation calculated using the Cockcroft-Gault 
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formula. Thus, cobicistat does not really alter glomerular filtration (22,23). It is now 
known that this drug restrains some cation renal transporters. However, no dosage 
adjustments are required for patients with a defective liver or kidney function (22).  
Regarding CYP3A4 inducers such as carbamazepine and rifabutin, cobicistat is not as 
effective as ritonavir when administered simultaneously with these drugs, since it 
mostly metabolized by CYP3A4 and CYP2D6 (22).  
2.7 CCR5-antagonist 
The CCR5-antagonist Maraviroc (MVC), was approved by both the Food and Drug 
Administration (FDA)  in the US and the European Medicines Agency (EMA) in 
Europe in 2007 (29). CCR5- antagonists were the first ever class of antiretroviral drugs 
to target host cells and not virions (19). Their advent rose from the need to introduce 
other drugs with different therapeutic targets, in order to solve the drug resistance with 
other molecules (19).  
As already discussed, CCR5, along with CXCR4, is one of the co-receptors present in 
TH4 lymphocytes that in turn allows the HIV virions to attach to it, and thereby, enter 
the immune cells. CCR5 is also the most common co-receptor, being present in the 
majority of target cells, which makes it a very promising therapeutic target (19).  
MVC will bind to the co-receptor’s hydrophobic pocket and induce a conformational 
change avoiding its recognition by viral gp120, thereby limiting virion entry into 
peripheral blood mononuclear cells (PBMC) (13,35).  
MVC is mostly metabolized in the liver by CYP450 enzymes, such as CYP3A4 and 
CYP3A5, which is why it should be administrated cautiously with other CYP450 
inducing or inhibiting drugs, such as PIs (35). 
As previously mentioned, in the early stages of HIV progression, CCR5 is the dominant 
co-receptor. However, as the disease progresses, CXCR4 becomes more and more 
frequent, and therefore, MVC will not be as effective as in the early stages (19), 
Furthermore, it is known that some mechanisms of resistance involve mutations which 
cause a higher affinity of gp120 towards CCR5 already connected to MVC (35). As for 
adverse effects, among the most common ones are nausea, diarrhea, fatigue and 
headaches (20). 
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At least, some examples of combination antiretroviral therapy (c-ART) can be seen in 
Table 2. 





Active Substances References 
Genvoya® 
150mg elvitegravir/ 150 mg cobicistat/ 200mg emtricitabine/ 10 
mg tenofovir 
(36) 
Atripla® 600mg efavirenz/ 200mg emtricitabine/ 245mg tenofovir-DF (37) 
Rezolsta® 800mg darunavir/ 150mg cobicistat (38) 
Triumeq® 50mg dolutegravir/ 600mg abacavir/ 300mg lamivudine (39) 
Evotaz® 300mg atazanavir / 150mg cobicistat (40) 
Descovy® 
200mg emtricitabine / 10mg tenofovir alafenamide 
200mg emtricitabine / 25mg tenofovir alafenamide 
(41) 
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3. New Drugs and Vaccines – Overview of Phase III Clinical Trials 
Nowadays the wide range of therapeutic options and c-ART regimens available have 
allowed for HIV to become a chronic infection, rather than a deadly condition, as it was 
considered initially (42). Although c-ART is the best therapeutic strategy at the 
moment, is not the ideal solution, given that patients experience several side effects and 
are forced to life-long medication with a considerable risk of emergence of a resistant 
viral strain and rebound in viral load due to the virus’ reservoir (43,44).  
When discussing a cure for the HIV virus, it is important to establish the difference 
between a “sterilizing cure” and a “functional cure”. A “sterilizing cure” consists of the 
elimination of both active infected cells and the virus’ latent reservoir, whereas a 
“functional cure” implies a prolonged suppression of viremia to an undetectable level 
and sustaining a normal CD4+ cell count (42).  
At the moment there are several new drugs and vaccines being tested in pre-clinical and 
clinical trials for HIV treatment or prophylaxis. In this chapter, most recent clinical 
studies on phase III will be further discussed. 
3.1 Post-attachment inhibitors: Ibalizumab  
Ibalizumab was approved in  March  2018 by the FDA and granted a “breakthrough 
therapy status” in 2015 (45). Its approval by the EMA is still pending at this time, 
although the agency has issued a positive opinion, recommending the granting of a 
marketing authorization for this drug on June 25th 2019 (46).  
At the moment, Ibalizumab is approved for treatment in combination with other drugs 
and in non-naïve patients, who have already been treated with other classes of 
antiretrovirals unsuccessfully, due to drug resistance. It is the first drug to target the 
CD4 receptor, and therefore, the first to be considered a post-attachment inhibitor 
(45,47).   
In molecular terms, as an IG4 monoclonal antibody (IG4 mAb), ibalizumab connects to 
domain 2 of the CD4 receptor and leads to conformational changes, thereby preventing 
HIV virions from entering the host cells (48). 
 In order to a viral particle enters a host cell, HIV must firstly bind to the T-cell through 
the CD4 T cell receptor. This is followed by the previously described interactions and 
conformational changes in the gp120 protein and its connection with the co-receptors 
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(48). Ibalizumab, in its turn, induces conformational changes in the CD4 receptor which 
avert the gp120 – co-receptor interactions, and consequently preventing viral entry. This 
action mechanism also explains why ibalizumab is effective against both R5 and X4 
viruses (48).  
There are few particular aspects that make ibalizumab an innovative therapeutic option. 
It does not cause CD4 depletion, due to important factors. Firstly, the specific epitope of 
the CD4 receptor to which it binds is distant from the allocation site of the MHC II 
molecule (21,48). Furthermore, ibalizumab has an IgG4 structure, which means that it 
has very low ADCC (anti-body dependent cellular cytotoxicity), hence a very low 
rapport towards cytotoxic immune responses. Therefore, CD4+ cells will not be 
destroyed through cytotoxic pathways (48). 
At the moment, the FDA recommends the subcutaneous administration of  2000mg 
loading dose, and subsequently, 800mg maintenance dose every 2 weeks (45).The 
drug’s half-life is estimated to range between 3 and 3.5 days (21,48). Ibalizumab is 
generally well tolerated, with adverse effects such as rash, headaches, nausea and 
depression being reported in a very low percentage of patients (48).  
In summary, ibalizumab presents as a very promising and safe therapeutic option for 
patients suffering from resistance to the recommended ARV regimens, and might also 
be more convenient when it comes to administration intervals, allowing for higher 
adherence to therapy and patient autonomy (21).   
 3.2 Long acting (LA) injectable Cabotegravir/Rilpivirine formulation  
Cabotegravir (CR) is an INSTI, structurally similar to dolutegravir (49,50). It is 
currently being developed as a tablet, to be administered once daily as well as a long 
acting injectable formulation, in combination with rilpivirine (50,51). CR’s half-life is 
particularly long, ranging between 20 to 40 days (50). CR is strongly bound to albumin 
and eliminated through the liver, however no dose adjustments are required for patients 
with an impaired hepatic function. (50). Rilpivirine is a NNRTI. It has also a long half-
life being a long-acting formulation and ranging from 30 to 90 days. It can cause 
headaches, nausea, dizziness and  fatigue and it might also interfere with liver and 
pancreatic enzymes (50).  
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Recently, the results from Phase III clinical trials on this formulation have been 
published (51). There are presently two trials regarding the impact of this formulation: 
FLAIR and ATLAS (50).  
FLAIR is an open-label Phase III trial. All the accepted patients were ART-naïve. Aside 
from K103N, none of them presented any other NNRTI resistance associated mutations 
(RAMs) (50).  
This trial was divided into two phases. The induction phase lasted for 20 weeks in 
which all patients took the oral fixed dose combination (FDC) of 
abacavir/lamivudine/dolutegravir. At week 20 began the maintenance phase, and all 
patients with less than 50 copies/ml were randomly distributed as to either remain with 
the initial therapy or start a different oral therapy regimen with 30mg cabotegravir + 25 
mg rilpivirine once a day for 4 weeks. Following the 4 week period, the patients were 
given a loading dose of 600mg cabotegravir + 900mg rilpivirine intramuscularly and 
afterwards a maintenance dose of LA cabotegravir 400mg + 600mg LA rilpivirine once 
a month (50,52,53).  
After 48 weeks, the assessment showed that 7 patients out of 283 doing oral therapy 
(2.5%) had over 50 copies of viral RNA/ml as opposed to 6 patients out of 283 taking 
the LA formulation (2.1%). However, there were patients in both arms of the trial that 
abandoned the study due to ineffectiveness and few other patients had confirmed 
virologic failure, which means that these drugs failed in keeping viral load under 200 
copies/ml. These results were enough to prove non-inferiority of LA injectable therapy 
in relation to oral therapy (47,50,52,54). Patients were generally satisfied with this new 
therapy regimen and injection site reactions (ISRs) were mostly mild and constrained 
(50). 
For the ATLAS study, also open-labeled and randomized, all the participants followed 
an oral therapy regimen with 2 NRTI + 1 INSTI, NNRTI or PI for a minimum of six 
months and all of them had less than 50 copies/ml of HIV RNA. The patients were 
distributed randomly to either continue with their usual regimen or enter the LA therapy 
arm. Similar to the FLAIR study, LA therapy patients received 30mg LA cabotegravir + 
25mg LA rilpivirine for 4 weeks. Afterwards, they were given through intramuscular 
injection  600mg of LA cabotegravir + 900mg LA rilpivirine as a loading dose and a 
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maintenance dose of 400mg LA cabotegrvir + 600mg rilpivirine, taken once a month, 
through the same route of administration (50,55,56). 
The results showed that after 48 weeks only 5 out of 308 patients doing LA therapy had 
over 50 copies of viral RNA/ml (1.6%), compared to 1.0% (3/308) in the control group. 
This means that LA cabotegravir + rilpivirine was considered non-inferior to triple oral 
therapy. Contrary to the FLAIR study, there was a higher incidence of adverse reactions 
(47,50).  
With both studies, it has been proven that LA injectable therapy has significant 
advantages when compared to oral therapy, like the low frequency of the injections. 
Most patients found this option preferable, however, there are still some concerns about 
this treatment option, such as viral resistance, how to proceed when they miss an 
injection or the possibility that this type of regimen might make patients less compliant 
to a medication schedule (50). Additionally, it is known that rifampicin activates CR’s 
metabolism, reducing its concentration in the plasma. This might cause a problem in 
HIV positive patients co-infected with Tuberculosis (TB), since rifampicin is commonly 
used to treat it (50).  
Despite these promising results, there are still some questions to be answered, such as 
LA therapy’s effect on women, and its use during pregnancy. At the moment, there are 
ongoing studies, such as MOCHA aimed to provide information regarding the 
pharmacokinetics and safety of using LA CR on adolescents from 12 to 18 years old 
and ALTAS 2M, which is looking into a different regimen of 600mg LA CR + 900mg 
LA rilpivirine every 8 weeks (50).  
3.3 Fostemsavir  
Fostemsavir was developed as a prodrug of temsavir, an attachment inhibitor. Its 
mechanism of action is innovative, as it connects to the viral glycoprotein gp120. 
Gp120 is then unable to bind to the CD4 receptor, and therefore viral entry is prevented 
(49,57,58). At the moment, the BRIGHTE study is an ongoing phase III clinical trial 
assessing the efficacy of this new drug. All participants are infected with multi-resistant 
HIV-1, not responding to therapy, and with a viral load of  over 400 copies/ml (58,59). 
Patients were assigned into two cohorts: one randomized (RC) and another non-
randomized (NRC). In the RC, patients were given either placebo or 600mg fostemsavir 
twice a day along with their failing ART drugs for 8 days. From the 9th day forward all 
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patients received 600mg fostemsavir twice daily along with optimized background 
therapy (OBT), just like the patients in the NRC (58,59).  
The results showed that there was a low prevalence of adverse effects, being the most 
frequent headaches, nausea and diarrhea (58,59). However, there were few patients who 
experienced more severe adverse effects such as acute renal failure and hepatocellular 
injury, among others (58). Fostemsavir has no registered major interactions with other 
classes of ARV drugs (58). Nevertheless, it is still needed more information about this 
new drug’s potential side effects and interactions. After 24 weeks, 146 out of 272 
patients in the RC (54%) had less than 40 copies of viral RNA/ml. In the NRC, the 
percentage of patients who had their viral load less than 40 copies/ml was 36% (36/99) 
(58,59).  
3.4 Leronlimab (PRO 140) 
Leronlimab is a humanized IgG4 monoclonal antibody. Its target is the CCR5 
chemokine receptor, since it binds to the extracellular domains of this molecule, such as 
loop 2 and the N-terminus (60,61). By this way, PRO 140 prevents virions from 
entering and infecting other host cells (60,61). Besides PRO 140, maraviroc’s 
therapeutic target is also the CCR5 co-receptor. However, there are few differences 
between these two drugs. Maraviroc binds to the transmembrane hydrophobic pocket of 
the co-receptor (60), and this difference in binding sites suggests that these drugs can be 
used synergistically together (62).   
There are currently ongoing phase IIb/III trials aiming to evaluate the safety and 
effectiveness of leronlimab. On one hand, there is CD 02, which evaluates leronlimab’s 
efficacy in patients with an unsuccessful ART regimen. They were given either 350mg 
of PRO 140 subcutaneously or placebo for 1 week along with their regular medication. 
One week later, participants were given PRO 140 with an optimized regimen. 
Unfortunately, the results were not very promising, since the failure rate was 76% due 
to the emergence of X4 viral strains, for which PRO 140 was ineffective (60).  On the 
other hand, there is CD 03, which is currently recruiting participants. This trial intends 
to test the transition of stable patients being treated with conventional therapy into a 
weekly regimen of subcutaneous leronlimab in monotherapy, by assessing the patients’ 
viral load for 48 weeks (63). 
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Nevertheless, this drug’s high tolerability and high threshold to resistance might make it 
suitable for pre and post exposure prophylaxis (60). 
3.5. UB-421  
 UB- 421 is an Fc-aglicosylated humanized IG1 antibody that targets the CD4 receptor. 
It prevents  attachment and viral entry by attaching to domain 1 of the receptor and 
blocking it in a competitive manner (64). 
At the moment, UB-421’s safety and efficacy are being assessed in several clinical 
trials. One of them is a phase II/III trial that started in September 2019. In this study, 
UB-421 is set to be assessed along with a failing ART regimen in an initial stage, which 
will last one week, and later, it will be evaluated with an optimized background regimen 
for 24 weeks. The primary outcome measure will be the viral loading log10 difference 
from the baseline (65).     
Additionally, there is a phase III study set to start in January 2020, in which the main 
goal is to evaluate the drug’s efficacy, safety and tolerability as a monotherapy agent. 
Participants will be distributed into two cohorts. Cohort 1 will consist of a control group 
taking standard c-ART, while in cohort 2 patients will take only UB-421 at 25mg/kg 
intravenously for 26 weeks bi-weekly. All patients will then enter a follow-up phase 
receiving standard c-ART. The primary outcome measure will be the number of patients 
without virologic failure (66).  
3.6 Vaccines  
The eminent need for an effective vaccine against HIV has been discussed over several 
years. However, despite various attempts, this goal has not been achieved yet. To this 
date, there have been few effective clinical trials for vaccines against HIV. The most 
promising one was a phase III RV144 trial, but it showed a low level of protection 
against the virus (67,68). One the main reasons for this viral resistance is based on the 
elevated variability of this virus which hinders finding a target that is common to so 
many different strains (67,69).  
Considering this extreme viral variability, a vaccine design based on live inactivated 
virus or attenuated virus may not be a viable strategy. Alternatively, the vaccines that 
have been currently tested, use attenuated viral proteins (such as gp120) in order to 
induce an immune response with the production of broadly neutralizing antibodies 
(70,71). 
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The target for neutralizing antibodies (nAb) is Env, and consequently, this is a suitable 
immunogen when designing a vaccine taken into account its role in viral targeting and 
entry. Another important aspect to consider is the delivery system for the vaccine. For 
example, nanoparticles have been shown as suitable carriers for vaccines (70,71).  
The vesicular stomatitis virus has already been tested as a viral vector for expression of 
heterologous genes from other viruses, such as Ebola and malaria (72).  It is now being 
tested as a vector for the expression of the env glycoprotein of HIV in order to induce 
the production of neutralizing antibodies (73).  
Accordingly, there is an ongoing clinical trial aiming to test a therapeutic vaccine for 
HIV in which a multiantigen DNA plasmid combined with an IL-12 plasmid (acting as 
adjuvants), and a vesicular stomatitis virus vector expressing the HIV-1 gag gene are 
tested. The goal of this vaccine is to increase humoral immune response in infected 
individuals, and possibly reactivating memory CD4 cells to eradicate latent reservoirs 
(74).  
When designing an HIV vaccine, synthetic proteins that are similar to the env trimer are 
also quite interesting, since they have been used to attempt the induction of an immune 
response against HIV. Gp140 is similar to env with exception of the gp120 subunit and 
the external part of the gp41 subunit (75). 
 A phase III clinical trial will be set to start later this year to assess the efficacy of a new 
vaccine containing mosaic antigens, such as env, gag-pol and gp140 (composed of 
gp120 plus the ectodomain of gp41) obtained from an adenovirus serotype 26 vector 
(76). This is an innovative challenge to formulate a “global vaccine” and overcome the 
major obstacle that is genetic diversity of HIV (77). 
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4. Novel Therapeutic Strategies 
4.1 New Transdermal Drug Delivery Systems  
Since most ARV are administered orally, it is important to identify the main adversities 
of oral ART such as bioavailability, frequency of administration and the hepatic first 
pass metabolism. Transdermal drug delivery systems (TDDS) are currently being 
investigated in order to diminish these issues (78–80).  
Thus, TDDS present as an alternative to the conventional oral ARV regimens, since this 
administration system allows for a controlled and continuous release of the drug, 
avoiding the pharmacokinetic variations of the oral administration. This means that it 
may be possible to use drugs with a short half-life, and find a simpler regimen for 
patients, and therefore, a higher compliance will certainly be achieved (78,79,81). 
In order to obtain a successful TDDS, it is important to understand the morphology of 
the skin. Briefly, the outer layer of the epidermis, the stratum corneum, is composed of 
dead queratinized cells, whose main function is to act as a barrier for any external 
agents (78,79).  
Transdermal drugs usually penetrate the skin mostly by diffusion and permeate through 
the stratum corneum, across the lipidic layers of the dermis, and finally, into the 
microvesssels of the skin. The ability of a certain drug to diffuse through the skin, or its 
skin permeability, is influenced by its physicochemical properties (78,79). The main 
ones include the drug concentration, pH, molecular weight (which should be low, 
ideally around 500 Da), log P (preferably ranged between 1 and 3) and the melting point 
(78–80).  
There are certain components that are essential in order to ensemble a TDDS. Besides 
the drug itself and its reservoir, a TDDS should have: a) permeation enhancers to 
increase the permeability through the stratum corneum (e.g. pyrrolidones, surfactants, 
phospholipids and solvents); b) pressure sensitive adhesives (PSA) to keep contact 
between the skin and the device; c) a release liner, to cover the patch, which could be 
considered part of primary packaging, and d) a backing layer which should not allow 
the diffusion of any excipients (78,79).  
4.1.1 Transdermal delivery system for Tenofovir Alafenamide 
Tenofovir Alafenamide (TAF) is a NRTI commonly used for HIV treatment as part of 
oral therapy regimens. A controlled matrix delivery system for this drug has been 
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studied recently  due to its low oral bioavailability (80). In this system, the active 
substance is dispersed in a polymer matrix and a suitable solvent which later evaporates, 
forming a drug reservoir. The reservoir is then shaped and interconnected with several 
layers. The overall system is composed of an adhesive layer that controls the release 
rate of the drug and is in contact with the skin, followed by the drug reservoir and a 
second adhesive layer, connected to an exterior impermeable laminate (78–80).  
Accordingly, the goal of this study (80) was to formulate a patch able to release TAF at 
8mg/day consistently for one week. Two types of patches were produced as silicone 
based or polyisobutylene (PIB) suspension patches and acrylate solution patches. For 
each patch, several formulations were prepared varying the components, TAF 
concentration and permeation enhancers. Each group of patches was evaluated for 
specific criteria, such as: a) crystallization of TAF in each matrix; b) effect of TAF 
particle homogenization; c) coat weight and TAF amount in each patch after exposure 
to stress conditions and d) in vitro skin permeation studies using Franz diffusion cells.  
Overall, the suspension silicone patch formulated with 15% TAF (w/w), silicone, oleic 
acid, oleyl alcohol and mineral oil as permeation enhancers revealed to be the most 
suitable one, since it presented the target flux permeation rate of 7 µg/cm2/h in a 50 cm2 
patch area for an entire week, reaching a daily dose of 8.4mg TAF. Additionally, this 
formulation was stable overtime, non-irritating to the skin and convenient when peeled 
off (80). Despite these positive results and the promising chance of a new route of 
administration for TAF, further studies are still needed regarding both pharmacokinetics 
and safety of this new device (80). 
4.1.2 Transdermal delivery of Enfuvirtide (T20) via ultrasounds 
As previously discussed, enfuvirtide (T20) is an entry inhibitor, usually administered by 
subcutaneous injection, 90mg twice a day, which makes it rather inconvenient in terms 
of patient compliance. Thus, its transdermal delivery could be an interesting option. 
However, there are some obstacles such as enfuvirtide’s high molecular weight (4492 
Da), which could compromise the diffusion through the stratum corneum (79,82).  
Nevertheless, ultrasound technique could be a way to surpass this problem, since it 
modifies the barrier function of the stratum corneum, enabling the diffusion of large 
molecules through the skin (83,84). Ultrasound waves are known to contribute to a fluid 
state of lipid skin layers, which in turn, promotes the transcellular pathway. Moreover, 
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ultrasound waves also create pores that allow large molecules to cross the epidermis 
(84,85). 
A recent study has assessed the effects of transdermal delivery of enfuvirtide using a 
low-frequency and low power ultrasound transducer patch in porcine models. The 
models were divided into 3 separate groups for 30 days as follows: one control group 
receiving injectable enfuvirtide twice a day; another group undergoing ultrasound 
treatment with saline solution and a third one being treated with transdermal enfuvirtide 
via ultrasounds (82).  
During the study, T20 was in direct contact with the skin. The final device was obtained 
using wound dressing patches and a silicone ring that served as a reservoir, over which 
the ultrasound transducer was placed (82).   
All groups were evaluated in order to understand the differences between them 
regarding skin health and bioavailability. The skin health criteria were based on 
histologic cuts and trans-epidermal water loss. Bioavailability of T20 was evaluated 
through liquid chromatography/electrospray ionization mass spectrometry (LC-MS/MS) 
(82).  
Regarding skin health, there were no significant differences between the saline group 
and the transdermal T20 group which indicates that ultrasound by itself did not affect 
the skin. The histologic cuts showed mild signs of inflammation in the active patch 
group. As for pharmacokinetics, the animals from the active patch group had a longer 
tmax and a lower Cmax when compared to the injectable T20 group. The plasma 
concentrations were generally lower with the transdermal treatment as expected (82). 
 
4.2 Nanosystems for Drug Delivery 
Nanotechnology has contributed for several applications in drug delivery through 
different routes of administration being quite useful in overcoming formulation 
obstacles, such as solubility, bioavailability and stability of the active substance (86). 
Additionally, nanosystems could be a strategy for targeted therapy since they allow the 
encapsulation of drugs or specific genes that could be transported not only to infected 
cells but also to reservoir tissues such as central nervous system (CNS) and lymph 
nodes, to potentially eradicate the virus (86). 
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There are several types of nanosystems that could function as carriers for ARV drugs, 
such as liposomes, niosomes, solid-lipid nanoparticles, polymeric nanoparticles, 
dendrimers among others (86).  
In general, liposomes and niosomes are less toxic and cost effective. Both are made of 
an aqueous compartment surrounded by a lipid bilayer. Stavudine was recently 
encapsulated into gelatin nanoparticles, which were in turn encapsulated into liposomes. 
Several formulations were prepared and characterized in terms of drug release, 
cytotoxicity and hemocompatibility (87). Liposomes revealed to be a promising 
alternative for drug delivery as these carriers can be easily absorbed by macrophages 
(87).  
Dendrimers are somewhat toxic, but have several reactive groups capable of forming 
conjugates for a targeted drug delivery (86,88). Dendrimers possess a typical three 
dimensional branched structure where the outer layers are appropriate for conjugation, 
while the inner layers are quite effective for drug encapsulation, resulting in a controlled 
drug release (88). In a recent study published in 2013, zidovudine was encapsulated into 
a poly (propyl ether imine) (PETIM) dendrimer, in an attempt to surpass the drug’s 
short half-life and provide a more continuous release (89). The study showed that not 
only did the formulation reduce AZT’s hemolytic effect, it also prolonged the drug’s 
release, decreasing the chance of side effects and insuring its slow and consistent 
liberation (89). In another study, carbosilane dendrimers (G3-S16 and G2-NF16) were 
used to encapsulate zidovudine, efavirenz and tenofovir (90). The encapsulated drugs 
were tested for antiviral activity in PBMC cells and TMZ-bl cells infected with X4 and 
R5 viral strains. The results showed an enlarged antiviral activity of all three drugs, 
when formulated with dendrimers (90). 
Polymeric nanoparticles such as quitosan and poly (lactide co-glicolide) (PGLA) are 
also known to be very effective in drug delivery while exhibiting low toxicity, just like 
metal gold or silver nanoparticles(86). Nanoparticles have been tested as a way to 
improve ARV drug delivery to the CNS. In fact, one of the main obstacles to ARV 
delivery in the CNS is the blood-brain barrier, since many ARV drugs suffer efflux 
mechanisms, which may contribute to the spreading of the virus in the CNS and thereby 
the development of HIV-related neurologic disorders (91,92). 
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Throughout the years, several formulations have been attempted in order to successfully 
deliver ARV drugs to the CNS (91). For example, transferrin is one of the nanoparticles 
studied to deliver these drugs to the CNS, due to the abundance of transferrin receptors 
in the blood-brain barrier (86,91). 
In a recent study, nanodiamond particles were characterized in order to understand if 
they were able to load efavirenz (EFV) and deliver it to the brain (93). This study 
compared nanodiamond particles (ND) with both unmodified and modified surface 
(ND-COOH and ND-NH2) in terms of toxicity, and drug loading capacity. ND-COOH 
was found to be less suitable than the other two, since it induced a higher production of 
reactive oxygen species (ROS) (93). Additionally, the formulation with unmodified 
nanodiamond particles (ND-EFV) presented a suitable and slower release profile 
through a blood-brain barrier model and was able to impair viral replication for a longer 
period in comparison with free EFV (93).  
Overall, this study illustrates that nanodiamond particles are a promising drug delivery 
system, due to their nontoxic nature and ability to cross the blood-brain barrier. 
However, further studies need to be performed in order to evaluate their effect in in vivo 
models and possible side effects, since ND particles may interfere with the expression 
of genes related to neuronal function (93).  
A recent study attempted to demonstrate the effects of using PGLA nanoparticles 
loaded with EFV and saquinavir (SQV) both individually and with free tenofovir (94). 
In general, ARV formulated with PGLA nanoparticles showed lower IC50 values in 
comparison with the free ARV drugs. The release profile of these nanoparticles was also 
quite favorable, since the drugs were first rapidly released, and afterwards, at a rather 
continuous rate. Additionally, when adding free tenofovir to the nanoparticles, a 
synergic effect was obtained resulting in dose reduction to impair HIV activity (94).  
In another report, PGLA nanoparticles were loaded with raltegravir (RAL) and EFV, 
and further incorporated in a thermo sensitive vaginal gel for HIV prophylaxis (95). The 
goal was to prepare a gel that would acquire a gel-like texture at 37ºC, while being 
liquid at room temperature. The PGLA nanoparticles were prepared via a modified 
emulsion-solvent evaporation method, and characterized through multiple experiments, 
including in vitro release studies with human cervical cells. When compared with an 
EFV-RAL solution, the loaded nanoparticles had a lower EC90 and were able to ensure 
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a constant release of these drugs, despite their different intracellular concentrations and 
routes of metabolization (95). Overall, the prepared formulation was considered a 
successful and promising option for pre-exposure HIV prophylaxis (95). 
Still regarding prophylaxis, cellulose acetate-phthalate (CAP) nanoparticles have shown 
promising outcomes when incorporated into thermosensitive gels. Most commonly used 
as a coating agent for other formulations, CAP was found to possess ARV activity by 
promoting viral disintegration and interfering with the mechanisms of viral entry. 
Moreover, CAP was stable at low pH, which facilitated a vaginal drug delivery (96,97).  
In fact, several studies have explored the potential of CAP nanoparticles in drug 
delivery. In another study (97), a thermosensitive gel was formulated using EFV loaded 
CAP nanoparticles. This formulation was assessed for cytotoxicity and prophylactic 
activity in human cervical cells (HeLa) and TZM-bl cells against an EFV solution. The 
results revealed a remarkable encapsulation efficacy as well as lower cytotoxicity in 
HeLa cells treated with EFV-CAP nanoparticles in the thermosensitive gel. Moreover, 
these nanoparticles showed enhanced prophylactic activity (at 5 ng/ml) in TMZ-bl 
indicator cells when compared with EFV solution (97).  
Similarly, dolutegravir (DTG) loaded CAP nanoparticles were incorporated into a 
thermosensitive gel and tested at pH= 4.2 and pH=7.4, in order to simulate vaginal and 
seminal fluid conditions, respectively (96).  In this study, pH influenced both the drug 
release and the cytotoxicity of the formulation (96).   
Accordingly, these examples of most recent in vitro studies regarding nanocarriers’ 
application for HIV therapy are listed in Table 3. 
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Nanocarriers + ARV Main Outcomes References 
Liposomes + Stavudine 
Liposomes revealed to be a promising alternative 
for stavudine delivery as these carriers can be 
easily absorbed by macrophages. 
(87) 
PETIM Dendrimer + 
Zidovudine 
The formulation reduced AZT’s hemolytic effect 
and it also prolonged the drug’s release, decreasing 
the chance of side effects and insuring its slow and 
consistent liberation. 
(89) 
Carbosilane Dendrimers + 
Zidovudine 
Carbosilane Dendrimers + 
Efavirenz 
Carbosilane Dendrimers + 
Tenofovir 
An enlarged antiviral activity of all three drugs was 
observed when formulated with dendrimers. 
(90) 
Nanodiamond Particles + 
Efavirenz 
A suitable and slower release profile through a 
blood-brain barrier model was obtained impairing 
viral replication for a longer period. 
(93) 
PGLA nanoparticles + 
Efavirenz 
PGLA nanoparticles + 
Saquinavir + 
Free Tenofovir 
An enlarged antiviral activity of all three drugs was 
obtained with PGLA nanoparticles. 
(94) 
PGLA nanoparticles + 
Efavirenz + Raltegravir 
(thermosensitive gel) 
A lower EC90 and a constant release of these 
loaded drugs were obtained being a promising 
option for pre-exposure HIV prophylaxis. 
(95) 
CAP nanoparticles + Efavirenz 
(thermosensitive gel) 
High encapsulation efficacy and lower cytotoxicity 
in HeLa cells besides enhanced prophylactic 
activity in TMZ-bl cells treated with EFV-CAP 
nanoparticles. 
(97) 
CAP nanoparticles + 
Dolutegravir 
(thermosensitive gel) 
pH (4.2 and 7.4) influenced both the drug release 
and the cytotoxicity of this formulation. 
(96) 
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5. Conclusion and Future Perspectives 
HIV infection is still considered one of the major pandemics worldwide. In the 90s, 
with the emergence of the first antiretroviral drugs and c-ART, the status of this 
infection changed from deadly illness to chronic infection, allowing infected people to 
live as long as a non-infected individual. However, c-ART presents many downsides, 
such as side effects, frequency of drug administration and the possibility of viral 
resistance, while still not providing a definitive cure. Several studies have been made in 
order shift the therapeutic strategies towards this infection.  
Various new drugs from the already well-known ARV drug classes and others with a 
novel therapeutic target have been evaluated in clinical trials. 
Moreover, some classical ARV drugs have been also studied in order to obtain a 
different route of administration, with a more prolonged drug release, in order to surpass 
some compliance issues derived from polymedication in HIV patients. 
Nanotechnology has shown to provide a more targeted and controlled release of 
antiretrovirals overcoming several formulation obstacles including cytotoxicity. 
Nevertheless, further investigation is urgently needed especially regarding prophylactic 
vaccines and pharmacokinetic/ pharmacodynamic in silico prediction followed by well-
defined in vivo studies. 
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ANNEX 
 
Table 4: Examples of drugs in preclinical, phases I and II clinical trials (adapted from (51)) 
Phase Drug Class 
Preclinical and Phase I 
Combinectine 
Entry inhibitor, targeting to gp41 and 
CD4 
GspI1 Protease Inhibitor 
GS – CA1 
Capsid Inhibitor (creates non-infectious 
virions) 
Phases I and II 
MK-8591 (EfdA) 
NRTI 
(could be used as a weekly oral dose or 
an annual implant for pre-exposure 
prophylaxis) 





Broadly neutralizing antibodies 






ABX464 Rev inhibitor 
GSK3640254 Maturation inhibitor 
 
